Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.49 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406088 | 0.85 | PTGS2 (0.71) | TP53ALOX12MAPTKMT2AMEN1 | |
| SCHEMBL10985613 | 0.84 | TP53 (0.74) | TP53KMT2AMEN1GAACA1 | |
| SCHEMBL16697767 | 0.83 | HTT (0.73) | TP53ALOX12MAPTKMT2APTGS2 | |
| SCHEMBL28634940 | 0.83 | TP53 (0.52) | TP53ALOX12MAPTKMT2AMEN1 | |
| SCHEMBL30808867 | 0.82 | TP53 (0.47) | TP53ALOX12MAPTKMT2AMEN1 | |
| SCHEMBL16697431 | 0.79 | SLC5A1 (0.46) | TP53KMT2AMEN1GAAHTT | |
| SCHEMBL18321160 | 0.76 | CYP1A2 (0.55) | MAPTKMT2AMEN1GAAHTT | |
| SCHEMBL15882211 | 0.73 | SMN1; SMN2 (0.77) | TP53ALOX12MAPTKMT2ASLC5A1 | |
| SCHEMBL23001698 | 0.72 | SMN1; SMN2 (0.75) | TP53ALOX12MAPTKMT2AGAA | |
| SCHEMBL17454416 | 0.72 | PTGS2 (0.68) | MAPTKMT2APTGS2HTTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | HOFFMANN-LA ROCHE INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | TP53 4825/4885ALOX12 397/4885MAPT 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.